International Journal of Epidemiology 2002;31:1016-1020
© International Epidemiological Association 2002
Special Theme: Infectious Diseases |
Incidence of morphological and lipid abnormalities: gender and treatment differentials after initiation of first antiretroviral therapy
a Centre for Excellence in HIV/AIDS.
b Canadian HIV Trials Network.
c Departments of Health Care and Epidemiology,
d Pathology and Laboratory Medicine,
e Department of Medicine, Faculty of Medicine, University of British Columbia.
Katherine Heath, BC Centre for Excellence in HIV/AIDS, 608–1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada. E-mail: kheath{at}hiunet.ubc.ca
Abstract
Objective To provide population-based incidence estimates for constituent symptoms of human immundeficiency virus (HIV)-related lipodystrophy syndrome and to identify possible independent predictors of accrued cases.
Design Prospective population-based cohort.
Methods Study subjects were antiretroviral-naïve individuals who initiated treatment between October 1998 and May 2001 and provided completed self-reported data regarding the occurrence of lipoatrophy, lipohypertrophy and increased triglyceride and cholesterol levels. Possible predictors of incident lipoatrophy, lipohypertrophy, dyslipidaemia and mixed lipodystrophy (symptoms of both lipoatrophy and lipohypertrophy) were identified using logistic regression modelling. A sub-analysis restricted to subjects retaining original treatment at study completion was conducted using similar methods.
Results Among the 366 study subjects, cumulative incidence was 29% for lipoatrophy, 23% for lipohypertrophy, 9% for dyslipidaemia, and 13% for mixed lipodystrophy after a median duration of 12 months of antiretroviral therapy. In an intentto-treat analysis incident lipoatrophy and lipohypertrophy were independently associated with initiation of protease inhibitor (PI)-containing regimens, (adjusted odds ratio [AOR] = 1.94; 95% CI: 1.25–3.03 and AOR = 1.76; 95% CI: 1.09–2.85, respectively) and female gender (AOR = 2.06; 95% CI: 1.03–4.12 and AOR = 2.36; 95% CI: 1.17–4.74, respectively). Both mixed lipodystrophy and reported dyslipidaemia were associated only with PI inclusion in the initial regimen (AOR = 2.27; 95% CI: 1.14–4.53 and AOR = 2.14; 95% CI: 1.26–3.65, respectively). Similar results were obtained in analysis of individuals retained in initial treatment groups throughout follow-up.
Conclusion Incident morphological and lipid abnormalities are common among individuals initiating first-time antiretroviral therapy. Use of PI was consistently associated with all lipodystrophy-related abnormalities after adjustment for a broad range of patient personal, clinical and treatment characteristics.
Keywords Lipodystrophy, dyslipidaemia, antiretrovirals, protease inhibitors
Accepted 12 June 2002
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  O. P. Flint, M. A. Noor, P. W. Hruz, P. B. Hylemon, K. Yarasheski, D. P. Kotler, R. A. Parker, and A. Bellamine The Role of Protease Inhibitors in the Pathogenesis of HIV-Associated Lipodystrophy: Cellular Mechanisms and Clinical Implications Toxicol Pathol, January 1, 2009; 37(1): 65 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Gkrania-Klotsas and A.-E. Klotsas HIV and HIV treatment: effects on fats, glucose and lipids Br. Med. Bull., December 1, 2007; 84(1): 49 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Nicastri, S. Leone, C. Angeletti, L. Palmisano, L. Sarmati, A. Chiesi, A. Geraci, S. Vella, P. Narciso, A. Corpolongo, et al. Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review J. Antimicrob. Chemother., October 1, 2007; 60(4): 724 - 732. [Abstract] [Full Text] [PDF]
|
|